Cargando…
Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma
Myxoid liposarcoma is the second most common liposarcoma. Although myxoid liposarcoma is relatively chemosensitive and thus a good candidate for chemotherapy, cases with relapsed or metastatic disease still have poor outcome. Here, we performed a gene microarray analysis to compare the gene expressi...
Autores principales: | Iura, Kunio, Kohashi, Kenichi, Hotokebuchi, Yuka, Ishii, Takeaki, Maekawa, Akira, Yamada, Yuichi, Yamamoto, Hidetaka, Iwamoto, Yukihide, Oda, Yoshinao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939879/ https://www.ncbi.nlm.nih.gov/pubmed/27499900 http://dx.doi.org/10.1002/cjp2.16 |
Ejemplares similares
-
Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas
por: Maekawa, Akira, et al.
Publicado: (2016) -
Prognostic value of nuclear morphometry in myxoid liposarcoma
por: Kawaguchi, Kengo, et al.
Publicado: (2023) -
Expression of Forkhead box M1 in soft tissue leiomyosarcoma: Clinicopathologic and in vitro study using a newly established cell line
por: Maekawa, Akira, et al.
Publicado: (2016) -
Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012) -
The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients
por: Pollack, Seth M.
Publicado: (2017)